Home » New Hair Loss Treatments Pipeline » RepliCel
Detailed information on the research project currently underway. We encourage you to bookmark these pages and check back often. Updates will be added periodically with new information on status, newly-released data, and clinical trial results. Back to New Hair Loss Research Pipeline
RepliCel technology RCH-01 is an autologous cell therapy making use of dermal sheath “cup cells” isolated from the hair follicle to treat Androgenetic Alopecia. These cells will be obtained from a small punch biopsy from the back of the subjects scalp, where hairs are immune to the hair loss process.
After this they will be replicated, and injected back into the balding area of subjects scalp. In a sense this is a “cellular hair transplant”, intending to migrate the beneficial genetic and cellular traits of alopecia-immune hairs to existing hairs in balding areas.
Autologous Cell Therapies for Normal Healing and Function